Infectious Diseases and Therapy
Aims and Scope
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Infectious Diseases and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of infectious disease therapies.
The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts.
Enhanced Digital Features
Infectious Diseases and Therapy is able to publish a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Every paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the key points of the content to a wider readership. Articles also have the option to include various other types of enhanced digital features including, but not limited to, slide sets, videos and video abstracts, infographics, podcasts and animations. All enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. They can either be submitted at the same time as the manuscript or can be submitted retrospectively, and there is no additional cost to publish these features.
By having a choice of media not limited to text, figures and tables alone, readers may receive information more efficiently, whilst being reassured that the content has undergone the same rigorous peer review as the original article. Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research.
For questions relating specifically to enhanced digital features, please contact firstname.lastname@example.org.
Plain Language Summaries
Articles published in Infectious Diseases and Therapy can be accompanied by Plain Language Summaries to assist non-experts (including non-specialists, patients, caregivers and others) in understanding important medical advances. These summaries can help the content to reach a broader audience thus supporting the effective dissemination of research.
Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.
At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments if appropriate.
Infectious Diseases and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
Upon acceptance of an article, authors will be required to pay the article processing charge of €340/ $380 per typeset page, which includes the rapid publication, open access, and other features mentioned above. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis.
For more information about the journal, including pre-submission enquiries, please contact email@example.com.
To view the rest of this content please follow the download PDF link above.